Roth Capital Reinstates Buy on LeMaitre Vascular, Announces $108 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Roth Capital analyst Kyle Bauser reinstates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and announces $108 price target.
Roth Capital analyst Kyle Bauser reinstates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and announces $108 price target.